Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves
Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves.
Think of Farxiga (dapagliflozin) as similar to Invokana (canagliflozin). They increase glucose excretion in the urine by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.
Both lower A1C by about 1%...decrease weight by about 4 to 7 pounds...modestly lower BP...and slightly increase LDL cholesterol.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: MD includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote